UCB will use Cradle’s AI-driven protein design platform in selected discovery projects, from hit generation through preclinical readiness, expanding its digital antibody engineering program.
|Articles|December 5, 2019
Bioprocess Academy to be Established by GE Healthcare and Guangzhou Development District
Author(s)BioPharm International Editors
GE Healthcare Life Sciences and Guangzhou Development District Investment Promotion Bureau have signed an agreement to jointly establish a training center for biopharmaceutical professionals.
Advertisement
According to a Dec. 4, 2019 press release, GE Healthcare Life Sciences and Guangzhou Development District Investment Promotion Bureau (GDD) have signed an agreement to jointly establish a training center for biopharmaceutical professionals.
The Guangzhou Bioprocess Academy will provide single-use bioprocessing training, aligned with good manufacturing practices (GMP) standards, for the latest biologic drug production processes. Delivery of the educational courses will be supported by GE Healthcare, which will also provide the single-use equipment.
“Guangdong is a strategic center for the development of China's biopharmaceutical industry,” said Emmanuel Ligner, president and CEO of GE Healthcare Life Sciences, in the press release. “This investment cooperation with GDD on professional training in the biopharmaceutical field is a new milestone in our continued investment in the China market and another way we fully support the development of the Chinese biopharmaceutical industry.”
“As a long-term partner of Chinese pharmaceutical enterprises, GE Healthcare Life Sciences has strong product lines, as well as the experience and expertise in biotechnology R&D, biopharmaceutical production and management training,” added Yu Lihua, general manager of GE Healthcare Life Science China, in the press release. “We are eager to collaborate with the government and the industry to build more professional and mature talent training bases, with this academy as a model, and support the growth of local talents.”
The Guangzhou BioProcess Academy is expected to open in September 2020 and there are plans for the academy to nurture collaborations with universities in the region so that an academic course on biomanufacturing can be developed in the future to encompass theory and practical learning.
Source:
Advertisement
Related to this article
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
ProBio grants AbTis exclusive global rights to a discovery-stage oncology antibody for development as a site-specific antibody-drug conjugate.
ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5